Evidence map›Paper›PMID 39499513›Full record

ArticleJAMA network open2024

Global Disparities of Cancer and Its Projected Burden in 2050.

Habtamu Mellie Bizuayehu, Kedir Y Ahmed, Getiye Dejenu Kibret, Abel F Dadi, Sewunet Admasu Belachew, Tanmay Bagade, Teketo Kassaw Tegegne, Rebecca L Venchiarutti, Kelemu Tilahun Kibret, Aklilu Habte Hailegebireal and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 216 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
216citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

216 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

156 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Habtamu Mellie BizuayehuRural Health Research Institute, Charles Sturt University, Orange, Australia.
Kedir Y AhmedRural Health Research Institute, Charles Sturt University, Orange, Australia.
Getiye Dejenu KibretSchool of Public Health, Faculty of Health, University of Technology Sydney, Ultimo, Australia.
Abel F DadiMenzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Sewunet Admasu BelachewSchool of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Tanmay BagadeCenter for Women's Health Research, College of Health, Medicine, and Wellbeing, The University of Newcastle, Callaghan, Australia.
Teketo Kassaw TegegneInstitute for Physical Activity and Nutrition, Deakin University, Geelong, Australia.
Rebecca L VenchiaruttiSydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
Kelemu Tilahun KibretGlobal Centre for Preventive Health and Nutrition, Institute for Health Transformation, Faculty of Health, Deakin University, Geelong, Australia.
Aklilu Habte HailegebirealSchool of Public Health, College of Medicine and Health Sciences, Wachemo University, Hosanna, Ethiopia.
Yibeltal AssefaSchool of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Md Nuruzzaman KhanCenter for Women's Health Research, College of Health, Medicine, and Wellbeing, The University of Newcastle, Callaghan, Australia.
Amanuel AbajobirSexual, Reproductive, Maternal, Newborn, Child and Adolescent Health Unit, Health and Wellbeing Theme, African Population and Health Research Center, Nairobi, Kenya.
Kefyalew Addis AleneSchool of Population Health, Faculty of Health Sciences, Curtin University, Perth, Australia.
Zelalem MengeshaHealth Research Institute, Faculty of Health, University of Canberra, Canberra, Australia.
Daniel ErkuHealth Economics and Financing Practice, Global Health Systems Innovation Group, Management Sciences for Health, Arlington, Virginia.
Daniel A EnquobahrieDepartment of Epidemiology, School of Public Health, University of Washington, Seattle.
Tsion Zewdu MinasDepartment of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Eyaya MisganDepartment of Gynecology and Obstetrics, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Allen G RossRural Health Research Institute, Charles Sturt University, Orange, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Cancer prevention and care efforts have been challenged by the COVID-19 pandemic and armed conflicts, resulting in a decline in the global Human Development Index (HDI), particularly in low- and middle-income countries. These challenges and subsequent shifts in health care priorities underscore the need to continuously monitor cancer outcome disparities and statistics globally to ensure delivery of equitable and optimal cancer prevention and care in uncertain times. Objective: To measure the global burden of 36 cancers in 2022 by sex, age, and geographic location and to project future trends by 2050. Design, Setting, and Participants: This cross-sectional study used population-based data from 2022 in 185 countries and territories were obtained from the Global Cancer Observatory database. Data extraction and analysis were carried out in April 2024. Main Outcomes and Measures: Counts, rates, prevalence, mortality to incidence ratios (MIRs), and demography-based projections were used to characterize current and future cancer burden. Results: This population-based study included 36 cancer types from 185 countries and territories. By 2050, 35.3 million cancer cases worldwide are expected, a 76.6% increase from the 2022 estimate of 20 million. Similarly, 18.5 million cancer deaths are projected by 2050, an 89.7% increase from the 2022 estimate of 9.7 million. Cancer cases and deaths are projected to nearly triple in low-HDI countries by 2050, compared to a moderate increase in very high-HDI countries (142.1% vs 41.7% for cancer cases and 146.1% vs 56.8% for cancer deaths). Males had a higher incidence and greater number of deaths in 2022 than females, with this disparity projected to widen by up to 16.0% in 2050. In 2022, the MIR for all cancers was 46.6%, with higher MIRs observed for pancreatic cancer (89.4%), among males (51.7%), among those aged 75 years or older (64.3%), in low-HDI countries (69.9%), and in the African region (67.2%). Conclusions and Relevance: In this cross-sectional study based on data from 2022, cancer disparities were evident across HDI, geographic regions, age, and sex, with further widening projected by 2050. These findings suggest that strengthening access to and quality of health care, including universal health insurance coverage, is key to providing evidence-based cancer prevention, diagnostics, and care.

Indexed as

COVID-19Global HealthNeoplasmsAdolescentAdultAgedAged, 80 and overCross-Sectional StudiesFemaleHealth Status DisparitiesHumansIncidenceMaleMiddle AgedPrevalenceSARS-CoV-2

Identifiers

PMID39499513
PMCPMC11539015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.